(P602) Comparing CGM Use vs. Non-Use in Clinically Eligible Patients: Cost and Utilization Impact

Despite strong clinical guidelines recommending continuous glucose monitors (CGMs) for individuals using rapid- or short-acting insulin, real-world adoption remains inconsistent. Many people who meet the clinical eligibility criteria for CGM do not have evidence of use, raising important questions about technology adoption, care delivery, and potential missed opportunities for improved diabetes outcomes. This poster describes research that explores healthcare utilization and cost differences between adults with insulin-treated diabetes who had evidence of CGM use and those who did not. Using a large national claims database, matched cohorts were constructed to isolate the impact of CGM on healthcare costs, emergency and inpatient utilization, glycemic management, and the occurrence of hypoglycemia and hyperglycemia over 12 months. By examining both clinical and economic impacts of CGM use versus non-use, this research informs more effective integration of technology into diabetes care and education strategies. Attendees will gain a deeper understanding of where gaps exist, how they may affect outcomes, and what actionable opportunities exist to better support people with diabetes through education, engagement, and individualized care.